Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02144051 · ClinicalTrials.gov registry record · Phase 1
Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
A Phase 1 study of Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 4
- Study locations
NCT02144051 is a Phase 1 study of Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor that has completed, run by AstraZeneca. The registered enrollment target is 32 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT02144051, a Phase 1 study of Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a first time in man (FTIM), Phase I study to determine the Maximum Tolerated Dose, Recommended Phase 2 Dose, safety, tolerability and Pharmacokinetics of AZD5312. This is a multicentre study with sites in the United States and United Kingdom. Approximately 90 patients are expected to be enrolled in this study. The study involves two parts, Part A, Dose Escalation and Part B, Dose Expansion.
Conditions Studied
Interventions
- DRUG AZD5312
Study Locations (4)
Florida
- Research Site - Sarasota
Tennessee
- Research Site - Nashville
Wisconsin
- Research Site - Milwaukee
Other
- Research Site - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02144051
The ClinicalTrials.gov registry entry for NCT02144051 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor appearing as the primary indexed condition, and to 1 intervention - of which AZD5312 is the first listed.
NCT02144051 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Tennessee, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02144051 about?
NCT02144051 is a clinical study titled "Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors". This is a first time in man (FTIM), Phase I study to determine the Maximum Tolerated Dose, Recommended Phase 2 Dose, safety, tolerability and Pharmacokinetics of AZD5312. This is a multicentre study with sites in the United States and United Kingdom. Approximately 90 patients are expected to be enro...
What is the current status of trial NCT02144051?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-05. Estimated completion is 2016-03.
What conditions does trial NCT02144051 study?
This clinical trial studies the following conditions: Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor.
What interventions are being tested in trial NCT02144051?
The interventions under investigation include: AZD5312 (DRUG).
Who is sponsoring clinical trial NCT02144051?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02144051 being conducted?
This trial has 4 study locations across Florida, Tennessee, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.